{"schema_version":"secwatch.filing_event.v1","accession":"0001999371-25-014216","form_type":"8-K","ticker":"TNXP","cik":"0001430306","company_name":"Tonix Pharmaceuticals Holding Corp.","filed_at":"2025-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.976675+00:00","generated_at":"2026-05-17T05:15:02.619020+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tonix sets Tonmya WAC at $1,860/month; appoints Ganesh Kamath as Head of Market Access","bullets":["Tonmya (cyclobenzaprine HCl sublingual tablets) approved Aug 15, 2025 for fibromyalgia; launch expected Q4 2025.","Wholesale acquisition cost (WAC) set at $1,860/month for 60-count supply; geriatric/mild hepatic: $930/month for 30-count.","Ganesh Kamath appointed Head of Market Access effective Sept 29, 2025; brings 25+ years experience from Bayer, Hutchmed, CuriaGlobal.","Kamath will lead pricing, contracting, and payer engagement for Tonmya launch and pipeline.","First new fibromyalgia prescription therapy in over 15 years; Tonix also markets two acute migraine treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0001999371-25-014216","json":"https://secwatch.observer/filing/0001999371-25-014216.json","markdown":"https://secwatch.observer/filing/0001999371-25-014216.md","text":"https://secwatch.observer/filing/0001999371-25-014216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/0001999371-25-014216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/tnxp-8k_093025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:15:02.619020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}